DE68909515D1 - Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen. - Google Patents

Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen.

Info

Publication number
DE68909515D1
DE68909515D1 DE89305461T DE68909515T DE68909515D1 DE 68909515 D1 DE68909515 D1 DE 68909515D1 DE 89305461 T DE89305461 T DE 89305461T DE 68909515 T DE68909515 T DE 68909515T DE 68909515 D1 DE68909515 D1 DE 68909515D1
Authority
DE
Germany
Prior art keywords
tumor cells
targeting
ligands
antibodies
cells affected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89305461T
Other languages
English (en)
Other versions
DE68909515T2 (de
Inventor
Sen-Itiroh Hakomori
Michiro Otako
Anil Singhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomembrane Institute
Original Assignee
Biomembrane Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomembrane Institute filed Critical Biomembrane Institute
Application granted granted Critical
Publication of DE68909515D1 publication Critical patent/DE68909515D1/de
Publication of DE68909515T2 publication Critical patent/DE68909515T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE89305461T 1988-07-01 1989-05-31 Durch Antikörper und Liganden bewirkte Zielrichtung von Differentiationsinduktoren auf Tumorzellen. Expired - Fee Related DE68909515T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21426188A 1988-07-01 1988-07-01

Publications (2)

Publication Number Publication Date
DE68909515D1 true DE68909515D1 (de) 1993-11-04
DE68909515T2 DE68909515T2 (de) 1994-03-03

Family

ID=22798404

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89305461T Expired - Fee Related DE68909515T2 (de) 1988-07-01 1989-05-31 Durch Antikörper und Liganden bewirkte Zielrichtung von Differentiationsinduktoren auf Tumorzellen.

Country Status (5)

Country Link
EP (1) EP0349127B1 (de)
JP (1) JPH02142489A (de)
AT (1) ATE95069T1 (de)
CA (1) CA1336760C (de)
DE (1) DE68909515T2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US7166295B1 (en) 1995-05-26 2007-01-23 Meir Strahilevitz Methods of treatment and diagnostic visualization, particularly in cancer
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US20110286937A1 (en) * 2008-02-22 2011-11-24 Gifu University Synthetic glycolipid-containing liposome

Also Published As

Publication number Publication date
ATE95069T1 (de) 1993-10-15
CA1336760C (en) 1995-08-22
EP0349127B1 (de) 1993-09-29
EP0349127A1 (de) 1990-01-03
DE68909515T2 (de) 1994-03-03
JPH02142489A (ja) 1990-05-31

Similar Documents

Publication Publication Date Title
DE3888186D1 (de) Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung.
DE69330643T2 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
ATE320448T1 (de) Gereinigte primate clta-8 antigene und verwandte reagenzien
ATE243754T1 (de) Multifunktionelle proteine mit vorbestimmter zielsetzung
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
DK0724456T3 (da) CD40-Antistoffer
DE3486030D1 (de) Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
MY105946A (en) Antagonists of gm-csf derived from the carboxyl terminus.
FI873410A (fi) Kahden uuden hybridooman tuottamia apolipoproteiini-B-spesifisiä monoklonaalisia vasta-aineita
DE68909515D1 (de) Durch antikoerper und liganden bewirkte zielrichtung von differentiationsinduktoren auf tumorzellen.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
ATE109834T1 (de) Monoklonaler antikörper spezifisch gegen humane pankreas-phospholipase-a2.
ATE56617T1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
DK0672685T3 (da) Monoklonalt antistof specifik for tumor cytotoxisk faktor (TCF-11)
DE59308875D1 (de) Monoklonaler Anti-Gangliosid-Antikörper, seine Herstellung und Verwendung als Tumortherapeutikum
DE3877015T2 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
DE3786695T2 (de) Tumorassoziiertes Antigen.
ATE34970T1 (de) Neue d-mannit-abkoemmlinge als vorprodukte zur synthese von phospholipiden.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee